Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Meditrina Pharmaceuticals
Germany's MediGene has signed yet another agreement for its treatment for genital warts, Veregen ointment (previously Polyphenon E), the latest deal being with Serbian company, Pharmanova, which will supply and commercialise the product in South-eastern Europe. The territories covered by the agreement include Serbia, Bosnia and Herzegovina, Montenegro, Macedonia, Croatia, Slovenia, and Albania.
The German biotech company MediGene has signed another licence and supply agreement for the commercialisation and marketing of Veregen (previously Polyphenon E) ointment for the treatment of genital warts, this time with SynCore Biotechnology in Taiwan.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
In Vivo briefly summarizes the technologies of these recently founded companies: Beacon Sciences, Bioconnect Systems, Brane Discovery, KC BioMediX, Meditrina Pharmaceuticals and Stemina Biomarker Discovery.
- Medical Devices
- Group Purchasing
- Home Infusion
- Consumables, Central Supplies
- Diagnostic Imaging Equipment & Supplies
- Implantable Devices
- Infection Control-Sterilization
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Radiofrequency Devices
- Rehabilitation Equipment and Devices
- Surgical Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools